Fresenius Medical Care, Global Medical Office, Bad Homburg, Germany.
Clinical Epidemiology of Renal Diseases and Hypertension Unit, Consiglio Nazionale delle Ricerche Institute of Clinical Physiology, Reggio Calabria, Italy.
Blood Purif. 2024;53(2):80-87. doi: 10.1159/000534604. Epub 2023 Nov 24.
The rapid advancement of artificial intelligence and big data analytics, including descriptive, diagnostic, predictive, and prescriptive analytics, has the potential to revolutionize many areas of medicine, including nephrology and dialysis. Artificial intelligence and big data analytics can be used to analyze large amounts of patient medical records, including laboratory results and imaging studies, to improve the accuracy of diagnosis, enhance early detection, identify patterns and trends, and personalize treatment plans for patients with kidney disease. Additionally, artificial intelligence and big data analytics can be used to identify patients' treatment who are not receiving adequate care, highlighting care inefficiencies in the dialysis provider, optimizing patient outcomes, reducing healthcare costs, and consequently creating values for all the involved stakeholders.
We present the results of a comprehensive survey aimed at exploring the attitudes of European physicians from eight countries working within a major hemodialysis network (Fresenius Medical Care NephroCare) toward the application of artificial intelligence in clinical practice.
An electronic survey on the implementation of artificial intelligence in hemodialysis clinics was distributed to 1,067 physicians. Of the 1,067 individuals invited to participate in the study, 404 (37.9%) professionals agreed to participate in the survey.
The survey showed that a substantial proportion of respondents believe that artificial intelligence has the potential to support physicians in reducing medical malpractice or mistakes.
While artificial intelligence's potential benefits are recognized in reducing medical errors and improving decision-making, concerns about treatment plan consistency, personalization, privacy, and the human aspects of patient care persist. Addressing these concerns will be crucial for successfully integrating artificial intelligence solutions in nephrology practice.
人工智能和大数据分析的快速发展,包括描述性、诊断性、预测性和规范性分析,有可能彻底改变医学的许多领域,包括肾脏病学和透析。人工智能和大数据分析可以用于分析大量的患者病历,包括实验室结果和影像学研究,以提高诊断的准确性、增强早期检测、识别模式和趋势,并为肾脏病患者制定个性化的治疗计划。此外,人工智能和大数据分析可用于识别未得到充分治疗的患者,突出透析提供者护理效率低下的问题,优化患者预后,降低医疗成本,并为所有相关利益相关者创造价值。
我们展示了一项全面调查的结果,该调查旨在探讨来自八个国家的在大型血液透析网络(费森尤斯医疗保健肾康)工作的欧洲医生对人工智能在临床实践中的应用的态度。
一项关于在血液透析诊所实施人工智能的电子调查分发给了 1067 名医生。在受邀参与研究的 1067 人中,有 404 名(37.9%)专业人员同意参与调查。
调查显示,相当一部分受访者认为人工智能有可能帮助医生减少医疗事故或错误。
虽然人工智能在减少医疗错误和改善决策方面的潜在好处得到了认可,但人们仍然对治疗计划的一致性、个性化、隐私和患者护理的人文方面表示担忧。解决这些问题对于成功将人工智能解决方案整合到肾脏病学实践中至关重要。